North America Organoids Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The North America organoids market is projected to grow significantly, reaching approximately USD 6,574.44 million by 2031, up from USD 1,357.19 million in 2023, reflecting a compound annual growth rate (CAGR) of 21.8% from 2023 to 2031.

Executive Summary and Market Analysis

The North America organoids market is divided into three main regions: the United States, Canada, and Mexico. As of 2023, the United States dominates the market, driven by an increasing prevalence of chronic diseases and viral infections, the commercialization of organoid models, heightened research and development activities, and advancements in stem cell research. Additionally, the rise in grants and funding for organoid research is further fueling market growth.

Market Segmentation Analysis

The North America organoids market can be analyzed through various segments, including type, application, source, offering, and method:

Type: The market is categorized into organoids derived from the intestine, liver, stomach, pancreas, lung, brain, kidney, and others. In 2023, intestinal organoids held the largest market share.
Application: The applications of organoids are segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery, personalized medicine, and others. Developmental biology applications led the market in 2023.
Source: The market is divided into organoids sourced from pluripotent stem cells and organ-specific adult stem cells, with pluripotent stem cells holding a larger market share in 2023.
Offering: This segment includes instruments, consumables, and services, with consumables being the largest segment in 2023. Instruments are further divided into devices and equipment, while consumables include sensors and other items.
Method: The methods used in organoid development include micropatterned plates, ultralow attachment plates, hanging drop, microdroplet or emulsion techniques, and others. The hanging drop method was the most prominent in 2023.

Market Outlook

Technological advancements are paving the way for integrating organoids with organ-on-a-chip technologies, enhancing applications in biological and biomedical research, particularly in disease modeling and clinical drug screening. Organoids combined with organ-on-a-chip systems are transforming cancer research paradigms and offering tangible clinical benefits. The collaborative use of organoids with organ-on-a-chip and 3D bioprinting is enabling the creation of advanced cancer models to investigate tumor-stroma interactions, multiorgan tumor metastasis, and cancer-microenvironment dynamics.

The development of organoid-on-a-chip systems, which incorporate multiple organoids on a single chip, is an emerging area with significant potential. This innovative approach allows for comprehensive studies of multiorgan tumor metastases and interactions within the cancer microenvironment. Recent advancements have led to the creation of brain, liver, and intestinal organoids-on-chip, indicating a promising future for this segment.

Country Insights

The North American organoids market is primarily represented by the US, Canada, and Mexico, with the US holding the largest market share in 2023. Organoids are overcoming previous limitations in biomedical research, providing insights into human development, creating accurate disease models, and generating patient-specific tissues for regenerative medicine. Notable research initiatives, such as those at the Wyss Institute at Harvard University and Duke University, have led to the development of human ovarian organoids that support egg maturation, potentially aiding in treatments for infertility and ovarian cancer. This technology, licensed to Gameto, is being utilized to develop therapeutics for female reproductive health issues. Furthermore, the Center for Stem Cell and Organoid Medicine (CuSTOM) at Cincinnati Children's Hospital is advancing personalized regenerative therapies through innovative stem cell technologies and organoids, aiming to engineer patient-specific tissues for therapeutic use.

Company Profiles

Key players in the organoids market include STEMCELL Technologies Inc., Molecular Devices, LLC, Hubrecht Organoid Technology, Definigen, Organoid Therapeutics, Thermo Fisher Scientific Inc., Corning Inc., Merck KGaA, InSphero, ACRO Biosystems, Bio-Techne Corp, SUN bioscience SA, ORGANOID SCIENCES Co., Ltd., Crown Bioscience Inc., Sartorius AG, 3D Biotek LLC, Prellis Biologics Inc., 3Dnamics Inc., and Cellesce Ltd. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative solutions to consumers.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America organoids market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in North America organoids market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the organoids market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Show more